The effect and safety of anlotinib combined with irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: A single-arm phase I study.

e20583Background: Current standard of care for SCLC relapsed within six months after first-line treatment was mainly chemotherapy alone, such as irinotecan or docetaxel, of which the clinical benef...